97 related articles for article (PubMed ID: 17662692)
21. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
23. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Sorolla A; Yeramian A; Dolcet X; Pérez de Santos AM; Llobet D; Schoenenberger JA; Casanova JM; Soria X; Egido R; Llombart A; Vilella R; Matias-Guiu X; Marti RM
Br J Dermatol; 2008 Mar; 158(3):496-504. PubMed ID: 18205878
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibitors: poisons and remedies.
Meiners S; Ludwig A; Stangl V; Stangl K
Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
29. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
Fennell DA; Chacko A; Mutti L
Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
[TBL] [Abstract][Full Text] [Related]
30. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
31. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
33. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202
[TBL] [Abstract][Full Text] [Related]
34. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
Nickeleit I; Zender S; Sasse F; Geffers R; Brandes G; Sörensen I; Steinmetz H; Kubicka S; Carlomagno T; Menche D; Gütgemann I; Buer J; Gossler A; Manns MP; Kalesse M; Frank R; Malek NP
Cancer Cell; 2008 Jul; 14(1):23-35. PubMed ID: 18598941
[TBL] [Abstract][Full Text] [Related]
35. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
37. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
[TBL] [Abstract][Full Text] [Related]
40. A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
McConkey DJ
Cancer Cell; 2008 Jul; 14(1):1-2. PubMed ID: 18598936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]